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1. INTRODUCTION {#jcmm14208-sec-0001}
===============

Thyroid cancer is the most commonly diagnosed cancer in Korea,[1](#jcmm14208-bib-0001){ref-type="ref"} and its incidence continues to rise worldwide.[2](#jcmm14208-bib-0002){ref-type="ref"} Current treatment options for papillary thyroid cancer (PTC) include surgery, radioactive iodine ablation, and thyroid hormone replacement.[3](#jcmm14208-bib-0003){ref-type="ref"} Although thyroid cancer is associated with a generally favorable prognosis, a minority of patients with thyroid cancer experience recurrence or distant metastasis.[3](#jcmm14208-bib-0003){ref-type="ref"} Therefore, the challenge remains to distinguish between patients with indolent or aggressive thyroid cancer. An accurate risk stratification of thyroid cancer is essential in order to select the most suitable treatment options. In 2015, the American Thyroid Association proposed a model including low‐, intermediate‐, high‐risk groups for differentiated thyroid cancer (DTC) mostly based on histologic report after surgery.[3](#jcmm14208-bib-0003){ref-type="ref"}

However, understanding of the molecular basis of pathogenesis and progression in thyroid cancer has progressed.[4](#jcmm14208-bib-0004){ref-type="ref"} Genetic mutations in genes such as BRAF, and RAS are associated with both the pathogenesis of DTC and prognosis of thyroid cancer.[5](#jcmm14208-bib-0005){ref-type="ref"} In the era of precision medicine, personalized treatment according to potential prognosis for individuals with thyroid cancer is critically important.

Big data have been mass produced for customized diagnosis; however, many medical scientists still use traditional statistical methods such as univariate Cox analysis (1972), the least absolute shrinkage selection operator (Lasso, 1997) and Elastic Net (2005) regression to predict survival.[6](#jcmm14208-bib-0006){ref-type="ref"}, [7](#jcmm14208-bib-0007){ref-type="ref"} Although these methods have been widely used in survival analysis, they do not incorporate the most up‐to‐date information regarding the complex interplay between biological pathways. A novel variable selection method, so‐called Network‐Regularized high‐dimensional Cox‐regression, has been developed that takes into account signalling pathways and gene networks with the addition of an optional gene‐gene correlation matrix.[7](#jcmm14208-bib-0007){ref-type="ref"}, [13](#jcmm14208-bib-0013){ref-type="ref"}

A new strategy that uses individual information is crucial to accurately stratify patients with PTC. Therefore, we aimed to develop a novel risk scoring system for PTC based on gene networks using The Cancer Genome Atlas (TCGA).

2. METHODS {#jcmm14208-sec-0002}
==========

2.1. Data acquisition and characteristics {#jcmm14208-sec-0003}
-----------------------------------------

The primary and processed data were downloaded from the Genomic Data Commons Data Portal (<https://gdc-portal.nci.nih.gov/>) in January 2017. All TCGA data were available without restrictions in publications or presentations according to TCGA publication guidelines. We downloaded mRNA expression data, and clinical information, which was last updated lastly in May 2016. Of 509 cases, the following samples were excluded; metastatic tissues (n = 8); history of other malignancies (n = 33); history of neoadjuvant therapy (n = 4); missing data (n = 9). In total, 455 patients were included in this study.

2.2. Selection of genes and risk score {#jcmm14208-sec-0004}
--------------------------------------

We performed Network‐regularized high‐dimensional Cox regression (Net) using the R package *coxnet*(*version 0.2*) to evaluate the association between event‐free survival (EFS) and mRNA expression. The terms 'events' was used to refer to recurrence and/or progression. To obtain more significant results, optional parameters were required. We made a gene‐gene pathway matrix using six large databases (Biocarta, HumanCyc, KEGG, NCI, Panther, and Reactome) as a regularized parameter 'Ω' using the R package *graphite*. The mixing parameter α, which decides the balance between Lasso and Ridge, was determined with minimal cross‐validation error. The gene set was selected using Net and the 'leave‐one‐out cross‐validation (LOOCV)' method. LOOCV is the most exhaustive cross‐validation methods which train and test on all possible ways to divide the observation into a training and a validation set. Risk score was calculated as the level of expression of each gene, multiplied by the corresponding regression coefficients, consisting of 35 genes in total (Table [1](#jcmm14208-tbl-0001){ref-type="table"}). The cutoff (−5.769287) was determined with maximal Uno\'s c‐index.[14](#jcmm14208-bib-0014){ref-type="ref"} Lower risk scores indicated lower risk for recurrence/progression. The study protocol is presented in Figure [1](#jcmm14208-fig-0001){ref-type="fig"}.

###### 

Selection of genes and regression coefficients for risk score

  Variables   Regression coefficients
  ----------- -------------------------
  ADRA2B      −0.07606
  ADGRB2      −0.05483
  BHMT2       −0.03582
  CCBL2       −0.40997
  FAM69A      −0.0207
  FDXACB1     −0.1655
  FTSJ1       −0.06527
  IGFBP7      −0.01554
  LIMK2       −0.09033
  LOC644172   −0.09062
  PITRM1      −0.20857
  PRMT6       −0.62461
  RNF5P1      −0.15293
  RPL23AP7    −0.17061
  SCARF2      −0.11515
  SOCS2       −0.00483
  TMEM47      −0.06395
  TRIM13      −0.02674
  TSC22D3     −0.02379
  TSPAN13     −0.06588
  TSPAN9      −0.07819
  WFDC1       −0.03168
  B3GLCT      0.09959
  BRAP        0.047107
  BUB1        0.043702
  SAPCD2      0.051446
  CDC20       0.035296
  CHAF1B      0.117852
  HIST2H2BF   0.07194
  KHNYN       0.231944
  KIAA1191    0.02546
  LANCL2      0.859539
  RIBC2       0.048252
  TTK         0.103131
  ZWINT       0.056916
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![Study protocol](JCMM-23-3010-g001){#jcmm14208-fig-0001}

2.3. Statistical analysis {#jcmm14208-sec-0005}
-------------------------

Survival analysis was performed to predict EFS. Variables such as age, sex, histologic subtype, extrathyroidal extension (ETE), lymph node metastasis, distant metastasis, and risk score were assessed using Cox proportional hazard regression analysis. Variables with a p value less than 0.05 were selected for multivariate analysis. To evaluate discriminatory accuracy, we used the *survival* and *survAUC*: log‐rank test, Uno\'s c‐index for the time‐dependent area under the curve (AUC) and AUC value for t‐year. Survival variables with a c‐index of 0.75 or more were considered to have excellent predictive value for the continuous event time. An AUC value of 0.6 or more was considered acceptable for prediction of t‐year survival. Correlation analysis between risk score and clinical variables was performed by Pearson\'s Chi‐squared test Yates' continuity correction because Yates\' continuity correction is used in 2 × 2 contingency table when at least one cell of the table has an expected frequency smaller than 5. Statistical analysis was performed using R software version 3.5.0 (The R Foundation for Statistical Computing, 2018), GraphPad Prism 7 for Mac OS X (GraphPad Software Inc, San Diego, CA, USA), and MedCalc software package (ver. 12.6.0.0, MedCalc, Mariakerke, Belgium).

3. RESULTS {#jcmm14208-sec-0006}
==========

In total, 455 patients with PTC were included in this study (120 men, 335 women). The mean age was 45.8 years. Of 455 patients with PTC, 43 (9.5%) experienced recurrence/progression during follow‐up (37.0 ± 30.6 months). Patients' characteristics are summarized in Table [2](#jcmm14208-tbl-0002){ref-type="table"}.

###### 

Patients' baseline characteristics (n = 455)

  Variables                  No.
  -------------------------- -------------
  Age (years)                45.8 ± 15.1
  Sex                        
  Male                       120
  Female                     335
  Histology                  
  Papillary thyroid cancer   
  Classical                  323
  Follicular                 96
  Tall cell                  30
  Etc                        6
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3.1. Risk scoring system {#jcmm14208-sec-0007}
------------------------

We developed a risk scoring system to predict recurrence/progression of PTC. The risk score ranged between −8.841 and −3.425 for all patients. Time‐dependent receiver operating characteristic analysis showed an acceptable predictive AUC of between 0.902 and 0.943 (Figure [2](#jcmm14208-fig-0002){ref-type="fig"}). A c‐index for the whole course of time was excellent with a value of 0.910. As shown in Figure [3](#jcmm14208-fig-0003){ref-type="fig"}, the risk score was statistically significance (*P* \< 0.0001) for EFS as well as the presence of distant metastasis (*P* \< 0.0001).

![Time‐dependent receiver operating characteristic (ROC) analysis at indicated years](JCMM-23-3010-g002){#jcmm14208-fig-0002}

![Kaplan‐Meier estimates of event‐free survival (EFS) om papillary thyroid cancer patients according to risk score (A), and distant metastasis (B)](JCMM-23-3010-g003){#jcmm14208-fig-0003}

3.2. Statistical analysis {#jcmm14208-sec-0008}
-------------------------

Age (≧55 years), sex (male), histologic subtype (classical), ETE (present), lymph node metastasis (present), distant metastasis (present), and risk score (high) were analyzed in relation to EFS by univariate analysis. Older age (hazard ratio 2.0264, 95% confidence interval 1.1083‐3.7051, *P* = 0.0218), presence of ETE (2.0484, 1.1232‐3.7356, 0.0193), presence of distant metastasis (9.8551, 4.3503‐22.3256, \<0.0001), and high risk score (32.7945, 12.8901‐83.4343, \<0.0001) were significant predictors for EFS, and presence of lymph node metastasis showed a trend towards reduced EFS (1.7761, 0.9689‐3.2555, 0.0632). In multivariate analysis, the presence of distant metastasis (7.2418, 3.1351‐16.7279, \<0.0001), and higher risk score (30.7052, 11.9086‐79.1705, \<0.0001) were independent predictors for EFS (Figures [3](#jcmm14208-fig-0003){ref-type="fig"} and [4](#jcmm14208-fig-0004){ref-type="fig"}, Table [3](#jcmm14208-tbl-0003){ref-type="table"}). To identify the correlation between risk score and clinical variables, we performed Pearson\'s Chi‐squared test Yates' continuity correction (Table [4](#jcmm14208-tbl-0004){ref-type="table"}). Risk score was highly correlated with age (*P* = 0.009), Stage (*P* = 0.002), M stage (*P* = 0.005), N stage (*P* = 0.003) and ETE (*P* = 0.025) (Table [4](#jcmm14208-tbl-0004){ref-type="table"}).

![Heatmap of risk score, distant metastasis, and recurrence/progression](JCMM-23-3010-g004){#jcmm14208-fig-0004}

###### 

Univariate and multivariate analysis of event‐free survival (EFS)

  Variables                            Univariate   Multivariate                                             
  ------------------------------------ ------------ ----------------- ---------- --------- ----------------- ----------
  Age (≧55 years)                      2.0264       1.1083‐3.7051     0.0218                                 
  Sex (male)                           1.4431       0.7620‐2.7332     0.2603                                 
  Extrathyroidal extension (present)   2.0484       1.1232‐3.7356     0.0193                                 
  Histologic subtype (classical)       1.0767       0.5524‐2.0985     0.8282                                 
  Lymph node metastasis (present)      1.7761       0.9689‐3.2555     0.0632                                 
  Distant metastasis (present)         9.8551       4.3503‐22.3256    \<0.0001   7.2418    3.1351‐16.7279    \<0.0001
  Risk score (high)                    32.7945      12.8901‐83.4343   \<0.0001   30.7052   11.9086‐79.1705   \<0.0001

John Wiley & Sons, Ltd

###### 

Associations between the risk score and clinical variables

  Variables                  Risk group   *P* value    
  -------------------------- ------------ ------------ -------
  Age (years)                                          
  \<55                       256 (73.6)   64 (59.8)    0.009
  ≥55                        92 (26.4)    43 (40.2)    
  Sex                                                  
  Female                     256 (73.6)   79 (73.8)    1
  Male                       92 (26.4)    28 (26.2)    
  Stage                                                
  I & II                     342 (98.3)   98 (91.6)    0.002
  III & IV                   6 (1.7)      9 (8.4)      
  M stage                                              
  M0                         344 (98.9)   100 (93.5)   0.005
  M1                         4 (1.1)      7 (6.5)      
  N stage                                              
  N0                         209 (60.1)   46 (43.0)    0.003
  N1                         139 (39.9)   61 (57.0)    
  Extrathyroidal extension                             
  None                       259 (74.4)   67 (62.6)    0.025
  Resent                     89 (25.6)    40 (37.4)    
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4. DISCUSSION {#jcmm14208-sec-0009}
=============

In this study, a risk scoring system derived from mRNA expression values and the presence of distant metastasis were strong predictors for recurrence/progression in patients with PTC. The incidence of thyroid cancer continues to rise worldwide, including in Korea.[2](#jcmm14208-bib-0002){ref-type="ref"}, [15](#jcmm14208-bib-0015){ref-type="ref"} However, the survival rates for thyroid cancer are relatively good with a 5‐year rate of 97.3%.[16](#jcmm14208-bib-0016){ref-type="ref"} Conventional treatment of PTC involves a three‐tiered approach including surgery, radioactive iodine ablation, and replacement of exogenous thyroid hormone, which has remained unchanged since the 1950s.[3](#jcmm14208-bib-0003){ref-type="ref"}, [17](#jcmm14208-bib-0017){ref-type="ref"} In addition, several reports suggested only active surveillance of low‐risk PTC without surgery.[18](#jcmm14208-bib-0018){ref-type="ref"} In this regard, there is a need for new prognostic factors that predict recurrence/progression in thyroid cancer.

The study of cancer genomics have accelerated the convergence of discovery science and clinical medicine.[19](#jcmm14208-bib-0019){ref-type="ref"} The molecular characterization of thyroid cancer has begun to influence diagnosis and the overall treatment landscape. Genetic mutations such as BRAF, RAS, and RET are known to be prognostic markers in thyroid cancer.[5](#jcmm14208-bib-0005){ref-type="ref"} PTCs with BRAF mutations show a higher risk of recurrence and a higher risk of death.[5](#jcmm14208-bib-0005){ref-type="ref"} TERT mutation is also associated with aggressive clinicopathological characteristics and poorer prognosis in PTC.[20](#jcmm14208-bib-0020){ref-type="ref"} TCGA launched in 2013 with 33 different tumor types from 11 000 patients.[21](#jcmm14208-bib-0021){ref-type="ref"} Data from 507 patients with PTC were included in TCGA generated by raw sequencing, transcriptome profiling, simple nucleotide variation, and copy number variation.[21](#jcmm14208-bib-0021){ref-type="ref"} Using the data from TCGA, upregulation of SLC2A1, SLC2A3 and SLC2A14 were associated with increased risk of death in PTC patients,[22](#jcmm14208-bib-0022){ref-type="ref"} and downregulation of long non‐coding RNA271 was associated with increased recurrence.[23](#jcmm14208-bib-0023){ref-type="ref"} Previous studies have shown the prognostic value of specific genes for other cancers via traditional statistical methods such as Cox regression analysis, Lasso and Elastic net regression.[7](#jcmm14208-bib-0007){ref-type="ref"}, [9](#jcmm14208-bib-0009){ref-type="ref"}, [10](#jcmm14208-bib-0010){ref-type="ref"} These methods have several limitations; Cox regression analysis does not consider gene‐gene expression networks and biological pathways. Lasso and Elastic net regression do incorporate gene‐gene expression correlation by grouping variable selection methods; however, they do not consider biological pathways.[7](#jcmm14208-bib-0007){ref-type="ref"}, [13](#jcmm14208-bib-0013){ref-type="ref"} Therefore, genes with significant prognostic value as identified by in traditional approaches may have the weakness of overfitting, however, fit in their own dataset. In this study, to overcome these limitations, we developed a novel risk scoring system using Network‐Regularized high‐dimensional Cox regression analysis that incorporated biological pathways as a regularized parameter. To obtain more biological information, we constructed a gene‐gene pathway matrix using six largest pathway databases (Biocarta, HumanCyc, KEGG, NCI, Panther, and Reactome).

In this study, a total of 35 genes were included in risk score system. As lower risk scores indicate the favorable prognosis, the higher expression of 22 genes with a negative regression coefficient, and the lower expression of 13 with a positive regression coefficient corresponds to less recurrence/progression. Among 22 genes with a negative regression coefficient, loss of IGFBP7 expression showed a role in thyroid carcinogenesis,[24](#jcmm14208-bib-0024){ref-type="ref"} LIMK2 showed a potential role as a tumor suppressor,[24](#jcmm14208-bib-0024){ref-type="ref"} consistent with this study. However, SOCS‐2 proteins showed roles in development and pathogenesis of PTC,[25](#jcmm14208-bib-0025){ref-type="ref"} and higher TSPAN13 expression was associated with poor prognosis in a previous report by Li et al.[26](#jcmm14208-bib-0026){ref-type="ref"} Among 13 genes with a positive regression coefficient, higher BUB1 expressions were associated with aggressive nature,[27](#jcmm14208-bib-0027){ref-type="ref"} consistent with this study.

The mixing parameter α, which decides the balance between Lasso and Ridge, was determined with minimal cross‐validation error. The gene set was selected using Net and the 'leave‐one‐out' method for cross‐validation. Risk score was calculated as the level of expression of each gene, multiplied by the corresponding regression coefficients, consisting of 35 genes in total (Table [1](#jcmm14208-tbl-0001){ref-type="table"}). The cutoff (−5.769287) was determined with maximal Uno\'s c‐index.[14](#jcmm14208-bib-0014){ref-type="ref"} Lower risk scores indicated lower risk for recurrence/progression. The study protocol is presented in Figure [1](#jcmm14208-fig-0001){ref-type="fig"}.

In addition to a risk scoring system derived from mRNA, the presence of distant metastasis was an independent predictor of recurrence/progression in this study, which is consistent with a previous meta‐analysis.[28](#jcmm14208-bib-0028){ref-type="ref"} Sabet et al suggested that distinguishing synchronous from metachronous manifestation of distant metastases adds an important prognostic feature to risk stratification in DTC.[29](#jcmm14208-bib-0029){ref-type="ref"} However, as less than 5% of patients with PTC present with distant metastasis, and imaging modalities such as ^18^F‐Fluorodeoxyglucose positron emission tomography are not routinely recommended, the presence of distant metastasis may be scarcely detected.[3](#jcmm14208-bib-0003){ref-type="ref"}, [30](#jcmm14208-bib-0030){ref-type="ref"} Therefore, risk stratification according to the presence or absence of distant metastasis may be beneficial for a minority of patients with PTC. In this study, cutoff value of 55 years was used, which has been newly adopted in the American Joint Committee on Cancer (AJCC) staging system (8th edition).[3](#jcmm14208-bib-0003){ref-type="ref"} A recent analysis concluded that increasing the age from 45 to 55 years would help avoid overtreatment in 12% of patients, while improving the statistical validity of the model.[31](#jcmm14208-bib-0031){ref-type="ref"} Older age was associated with recurrence/progression in PTC with a hazard ratio of 2.0264. In addition, ETE of PTC predicted recurrence/progression in univariate analysis, but not multivariate analysis. Previous studies showed conflicting results regarding the prognostic value of ETE. According to a meta‐analysis by De‐Tao et al, minimal ETE is a risk factor for recurrence.[32](#jcmm14208-bib-0032){ref-type="ref"} However, it was excluded from the parameters for DTC in the AJCC 8th edition,[3](#jcmm14208-bib-0003){ref-type="ref"} and was considered useful for T3 staging in the AJCC 7th edition.[33](#jcmm14208-bib-0033){ref-type="ref"} In this study, 25.7% of PTCs had minimal ETE and 2.6% had macroscopic ETE, however, was not an independent predictor of recurrence/progression. There were several limitations to this study. All data were retrospectively collected and derived from TCGA. In addition, as a small number of patients died during follow‐up, we could not validate the risk scoring system with overall survival, or disease‐specific survival.

As the importance of personalized therapeutics in aggressive PTC increases, an accurate risk stratification system is increasingly required. In the current study, we developed a novel risk scoring system for PTC derived from mRNA expression values, which is an independent predictor of prognosis in PTC. Although some limitations exist, our results provide insight into the prognostic prediction of patients with PTC.
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